NCT04005144View on ClinicalTrials.gov

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 25, 2020

Primary Completion Date

October 1, 2022

Study Completion Date

October 1, 2022

Conditions
ALK Gene RearrangementLung Non-Small Cell CarcinomaProgressive DiseaseROS1 Gene RearrangementStage IIIB Lung CancerStage IIIC Lung CancerStage IV Lung CancerStage IVA Lung CancerStage IVB Lung Cancer
Interventions
DRUG

Binimetinib

Given PO

DRUG

Brigatinib

Given PO

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (2)

Takeda
Array BioPharma
All Listed Sponsors
collaborator

Takeda

INDUSTRY

collaborator

Array BioPharma

INDUSTRY

lead

University of California, San Francisco

OTHER